Dynactin (DCTN) is a multi-subunit protein encoded by DCTN genes for 6 subunits. In different diseases the DCTN genes may have different roles; therefore, we investigated the prognostic potential of DCTN mRNA expression in cutaneous melanoma (CM).
Background
Cutaneous melanoma (CM) is one of the most aggressive tumors of the skin and mucosa [1] , accounting for 6380 out of 9250 skin cancer-related deaths in the United States in 2017 [2] . With improved awareness and treatment options, the 5-year relative survival rate has reached 92% and the 10-year relative survival rate has reached 89% [3] . Still, early detection is important, as the prognosis is much better if the cancer is detected early. The primary treatment for CM is surgery, and adjuvant immunotherapy, immunotherapy, and targeted therapy drugs also are used to treat various stages of melanoma [3] .
Dynactin (DCTN) is a multi-subunit protein that drives retrograde transport in cells [4] [5] [6] [7] . The 6 subunits of DCTN are referred to as dynactin 1-6 (DCTN1-6). All subunits of DCTN are critical to the structure and function of DCTN [4, [8] [9] [10] . DCTN1 was shown to act as a fusion partner in some but not all Spitz tumors [11] as well as in non-small cell lung cancer (NSCLC) [12] . DCTN1 and DCTN3 are upregulated in sporadic ALS [13] . DCTN2 is upregulated in the osteosarcoma SJSA-1 cell line, but a link between its altered expression and the prognosis of CM has not been reported [14] . Another study showed that the intronic regions of DCTN6 pre-mRNA interact with the SPRIGHTLY long non-coding (lnc)RNA of melanoma [15] . Based on this evidence for pathogenic roles of mutations in DCTN subunits, we questioned whether mutations in DCTN genes are associated with CM.
According to these previous studies, DCTN1 and DCTN2 are expressed in human epidermal melanocytes [16] . However, the relationships between DCTN family members and CM patients have not been investigated. Therefore, in the present study, we investigated the prognostic value of the mRNA expression levels of individual DCTN subunits and conducted a joint-effects analysis using data from 459 CM patients available in the OncoLnc database based on the Cancer Genome Atlas.
Material and Methods

Patient and disease characteristics
We used The Metabolic gEne Rapid Visualizer (MERAV: http:// merav.wi.mit.edu/, accessed by November 5, 2017) to generate boxplots of the expression levels of DCTN subunits in normal tissue and primary CM tissue [17] . The Cancer Genome Atlas (http://tcga-data.nci.nih.gov/tcga, accessed by November 7, 2017) and OncoLnc (http://www.oncolnc.org/, accessed by November 8, 2017) [18] were searched to obtain the clinical information of 459 CM patients, including sex, age, body mass index (BMI), TNM stage, events, survival time, death status, and mRNA expression levels of DCTN1, DCTN2, DCTN3, DCTN4, DCTN5, and DCTN6 according to 50% cutoff values.
Correlation analysis and functional enrichment analysis
Pearson correlation coefficient analysis was used to identify correlations among DCTN family genes. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) v.6.8 (https://david.ncifcrf.gov/tools.jsp, accessed November 10, 2017) [19, 20] was used for analyses of functional enrichment, including gene ontology (GO) functional analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 
Survival analysis
For each DCTN mRNA, patients were divided into high-and low-expression groups according to a 50 th percentile cutoff. The prognosis of CM was evaluated based on overall survival (OS). The Kaplan-Meier estimator with a log-rank test was used to identify correlations between the 6 DCTN mRNAs and patient survival. Adjustment was made for race, age, sex, and TNM stage in the Cox proportional hazards regression model.
Joint-effects analysis
A joint-effects analysis was performed for the combination of genes identified as significant by the survival analysis. Groups were formulated by summarizing the selected expression of genes associated with better OS in one group, worse OS in another group, and others in the last group, as outlined in Tables 1-3 .
Statistical analyses
Kaplan-Meier survival analysis and the log-rank test were used to calculate OS and P values for all associations. The Cox proportional hazards regression model was used for uni-and MST -median survival time; HR -hazard ratio; CI -confidence interval. . Vertical scatter plots and survival curves were generated in GraphPad Prism v.7.0 (La Jolla, CA, USA).
Ethics statement
All data used in this study were obtained from a public database; therefore, approval of the study by an ethics committee was not required.
Results
Patient characteristics influencing survival and differential DCTN expression in CM
The detailed demographic and clinical data for the 459 included patients are provided in Table 4 . Race, age, and TNM stage were significantly associated with median survival time (MST; P=0.004, P=0.001, and P<0.001, respectively; Table 4 ). Boxplots illustrating differences in the expression of the 6 DCTN genes in normal skin tissue versus primary CM tissue were generated using MERAV (Figure 1 ). The median expression levels of DCTN2 and DCTN3 were higher in normal skin tissue than in primary CM tissue, whereas the median expression levels of DCTN5 and DCTN6 were higher in primary CM tissue than in normal skin tissue. The median expression levels of DCTN1 and DCTN4 did not differ significantly between normal skin tissue and primary tumor. -0.8 Figure 2A ). Interactions among the expression levels of DCTN1, DCTN2, DCTN3, DCTN4, DCTN5, and DCTN6 are shown in Figure 2B .
Scatter plots for the expression of the 6 genes according to the 50 th percentile cutoff are shown in Figure 2C .
The biological functions of the DCTN genes were evaluated according to the BP, MF, and CC categories for GO functional analysis ( Figure 2D ), and the results of KEGG pathway analysis are shown in Figure 2D .
Survival influence of differential DCTN gene expression
The results of univariate survival analysis were showed as Figure 3A -3F. The results showed that low expression levels of DCTN2 and DCTN5 separately were significantly associated Figure 3B , 3E). High expression of DCTN6 also was significantly associated with favorable OS (P=0.002; Figure 3F ). Table 5 ).
Survival influence of combinations of DCTN gene expression
Based on the DCTN genes identified as influential by the multivariate survival analysis, a joint-effects model was used to determine the combined effects of DCTN genes on the OS of CM patients. The different groups for this analysis were generated according to the expression of DCTN1, DCTN2, DCTN5, and DCTN6 (Tables 1-3 ). The Kaplan-Meier estimator with a log-rank test was used to evaluate the prognostic value of the gene expression combinations represented by each group (Figures 4, 5 ). In the analysis of low DCTN1, DCTN2, and DCTN5 expression with high DCTN6 expression, the combinations in groups I, IV, XII, X, XIII, XVI, i, iv, vii, and 1 were found to be more highly correlated with favorable OS (all P<0.05; Table 6 ). On the contrary, in the analysis of high expression of DCTN1, DCTN2, and DCTN5 and low DCTN6 expression, the combinations in groups III, VI, IX, XIII, XV, XVIII, iii, vi, ix, and 3 were found to be more highly correlated with poor OS (all P<0.05; Table 6 ).
Discussion
The 6 DCTN genes are known to encode the 6 subunits of DCTN, which are all essential for the DCTN activity of driving retrograde transport in cells [4] [5] [6] [7] . Specific functions of individual DCTN subunits have also been reported. In human epidermal melanocytes, DCTN1 expression was detected in the dendrite tips, and DCTN2 expression was also localized in the perinuclear area and dendrite tips [16] . Notably, overexpression of 
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DCTN3 is lethal to cells, and overexpression of DCTN2 leads to the disruption of the Golgi apparatus [6, 22] . Mutations of DCTN1 have been identified in many serious motor neuron diseases, including ALS, ALS-frontotemporal dementia ALS/FTD, and PS [23] [24] [25] [26] [27] [28] , and a mutation in DCTN4 was linked to Pa airway infection, chronic Pa infection, and mucoid Pa in cystic fibrosis patients [29, 30] . Finally, the interaction between DCTN4 and the P-type ATPase (ATP7B) is a key component of Wilson disease [31] .
Most studies to date have investigated associations between DCTN genes and nervous system diseases, infection diseases, both through functional studies and mutational studies. Only a few reports have been published on connections between DCTN 
DCTN2 and DCTN5, (E) DCTN2 and DCTN6, and (F) DCTN5 and DCTN6. I, low DCTN1+low DCTN2; III, high DCTN1+high DCTN2; IV, low DCTN1+low DCTN5; VI, high DCTN1+high DCTN5; VII, low DCTN1+high DCTN6; IX, high DCTN1+low DCTN6; X, low DCTN2+low DCTN5; XII, high DCTN2+high DCTN5; XIII, low DCTN2+high DCTN6; XV, high DCTN2+low DCTN6; XVI, low DCTN5+high DCTN6; XVIII, high DCTN5+low DCTN6; II, V, VIII, XI, XIV, and XVII correspond to other combinations of genes as detailed in Table 1 . Tables 2 and 3 . genes and cancer, although the DCTN family may play a crucial role in some cancers via their effect of the function and structure of DCTN. For example, it was reported that DCTN1 and DCTN2 could coprecipitate with human EB1, which may be correlated with human adenomatous polyposis coli in vivo [32] . Most relevant to our study, the intronic regions of DCTN6 pre-mRNA were shown to interact with the SPRIGHTLY lncRNA of melanoma [15] . Still, there were no reports about the connection between DCTN mRNA expression and the prognosis of CM. Here, we used data for DCTN mRNA expression and clinical information in CM patients from the OncoLnc database according to the Cancer Genome Atlas to investigate the correlation of DCTN family mRNA expression and prognosis in CM patients and assess whether expression of any DCTN genes, individually or in combination, could be used as biomarkers for predicting prognosis in CM.
In our study, we found high expression levels of DCTN2 and DCTN5 in normal tissue, while the Kaplan-Meier curves from univariate survival analysis showed that low expression of DCTN2 and DCTN5 in tumor tissue was correlated with favorable OS in all CM patients, suggesting that DCTN2 and DCTN5 act as oncogenes in CM. In contrast, DCTN6 was highly expressed in primary skin tumor tissue, and high expression of DCTN6 was found to be correlated with favorable OS. This may be because DCTN6 can act as a tumor suppressor. DCTN2 was downregulated in CM but upregulated in the SJSA-1 osteosarcoma cell line [14] 
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human epidermal melanocytes [16] , suggesting that the mutations of DCTN1 and DCTN2 are important components of CM, and downregulated expression of these 2 genes may predict a favorable prognosis in CM.
The joint-effects analysis showed that expression of DCTN1, DCTN2, and DCTN5 at low levels and DCTN6 at a high level were correlated with a favorable OS in CM patients. In contrast, high expression of DCTN1, DCTN2, and DCTN5 and low expression of DCTN6 were correlated with poor OS.
There were some limitations in our study. First, a larger sample size is required to increase the reliability of our results. Second, more clinical data are required from further studies, including smoke and alcohol history, main tumor size, tumor sites in areas exposed or not exposed to the sun, anti-therapy status, radical resection status, family history, and pathological diagnosis, as well as data for more races among Asian and African populations. Thirdly, the patient data in our study were exclusively from a single source; therefore, the results need to be validated in another group. Despite these limitations, our study is the first to report that downregulation of DCTN1, DCTN2, and DCTN5 and upregulation of DCTN6 in CM are associated with a favorable prognosis. These 4 genes may be used as a prognostic biomarker panel in CM patients.
Conclusions
Our study demonstrated that low mRNA expression of DCTN1, DCTN2, and DCTN5 and high mRNA expression of DCTN6 were individually and jointly correlated with favorable prognosis among CM patients. Those 4 genes may be used as potential prognostic biomarkers in CM patients. Due to the small sample size and limited clinical information available in this study, these results need to be confirmed in further studies.
